Growth of malignant non-CNS tumors alters brain metabolome

Anna Kovalchuk, Lilit Nersisyan, Rupasri Mandal, David Wishart, Maria Mancini, David Sidransky, Bryan Kolb, Olga Kovalchuk

Research output: Contribution to journalArticle

Abstract

Cancer survivors experience numerous treatment side effects that negatively affect their quality of life. Cognitive side effects are especially insidious, as they affect memory, cognition, and learning. Neurocognitive deficits occur prior to cancer treatment, arising even before cancer diagnosis, and we refer to them as "tumor brain." Metabolomics is a new area of research that focuses on metabolome profiles and provides important mechanistic insights into various human diseases, including cancer, neurodegenerative diseases, and aging. Many neurological diseases and conditions affect metabolic processes in the brain. However, the tumor brain metabolome has never been analyzed. In our study we used direct flow injection/mass spectrometry (DI-MS) analysis to establish the effects of the growth of lung cancer, pancreatic cancer, and sarcoma on the brain metabolome of TumorGraft™ mice. We found that the growth of malignant non-CNS tumors impacted metabolic processes in the brain, affecting protein biosynthesis, and amino acid and sphingolipid metabolism. The observed metabolic changes were similar to those reported for neurodegenerative diseases and brain aging, and may have potential mechanistic value for future analysis of the tumor brain phenomenon.

Original languageEnglish (US)
Article number41
JournalFrontiers in Genetics
Volume9
Issue numberFEB
DOIs
StatePublished - Feb 20 2018

Fingerprint

Metabolome
Brain Neoplasms
Growth
Brain
Neoplasms
Neurodegenerative Diseases
Sphingolipids
Metabolomics
Protein Biosynthesis
Pancreatic Neoplasms
Sarcoma
Cognition
Survivors
Lung Neoplasms
Mass Spectrometry
Quality of Life
Learning
Amino Acids
Injections
Therapeutics

Keywords

  • Animal models
  • Brain aging
  • Metabolomics/metabolite profiling
  • Non-CNS tumors
  • Tumor brain

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Genetics(clinical)

Cite this

Kovalchuk, A., Nersisyan, L., Mandal, R., Wishart, D., Mancini, M., Sidransky, D., ... Kovalchuk, O. (2018). Growth of malignant non-CNS tumors alters brain metabolome. Frontiers in Genetics, 9(FEB), [41]. https://doi.org/10.3389/fgene.2018.00041

Growth of malignant non-CNS tumors alters brain metabolome. / Kovalchuk, Anna; Nersisyan, Lilit; Mandal, Rupasri; Wishart, David; Mancini, Maria; Sidransky, David; Kolb, Bryan; Kovalchuk, Olga.

In: Frontiers in Genetics, Vol. 9, No. FEB, 41, 20.02.2018.

Research output: Contribution to journalArticle

Kovalchuk, A, Nersisyan, L, Mandal, R, Wishart, D, Mancini, M, Sidransky, D, Kolb, B & Kovalchuk, O 2018, 'Growth of malignant non-CNS tumors alters brain metabolome', Frontiers in Genetics, vol. 9, no. FEB, 41. https://doi.org/10.3389/fgene.2018.00041
Kovalchuk A, Nersisyan L, Mandal R, Wishart D, Mancini M, Sidransky D et al. Growth of malignant non-CNS tumors alters brain metabolome. Frontiers in Genetics. 2018 Feb 20;9(FEB). 41. https://doi.org/10.3389/fgene.2018.00041
Kovalchuk, Anna ; Nersisyan, Lilit ; Mandal, Rupasri ; Wishart, David ; Mancini, Maria ; Sidransky, David ; Kolb, Bryan ; Kovalchuk, Olga. / Growth of malignant non-CNS tumors alters brain metabolome. In: Frontiers in Genetics. 2018 ; Vol. 9, No. FEB.
@article{64ee43cb2c4d4cc29017559224d28a7d,
title = "Growth of malignant non-CNS tumors alters brain metabolome",
abstract = "Cancer survivors experience numerous treatment side effects that negatively affect their quality of life. Cognitive side effects are especially insidious, as they affect memory, cognition, and learning. Neurocognitive deficits occur prior to cancer treatment, arising even before cancer diagnosis, and we refer to them as {"}tumor brain.{"} Metabolomics is a new area of research that focuses on metabolome profiles and provides important mechanistic insights into various human diseases, including cancer, neurodegenerative diseases, and aging. Many neurological diseases and conditions affect metabolic processes in the brain. However, the tumor brain metabolome has never been analyzed. In our study we used direct flow injection/mass spectrometry (DI-MS) analysis to establish the effects of the growth of lung cancer, pancreatic cancer, and sarcoma on the brain metabolome of TumorGraft™ mice. We found that the growth of malignant non-CNS tumors impacted metabolic processes in the brain, affecting protein biosynthesis, and amino acid and sphingolipid metabolism. The observed metabolic changes were similar to those reported for neurodegenerative diseases and brain aging, and may have potential mechanistic value for future analysis of the tumor brain phenomenon.",
keywords = "Animal models, Brain aging, Metabolomics/metabolite profiling, Non-CNS tumors, Tumor brain",
author = "Anna Kovalchuk and Lilit Nersisyan and Rupasri Mandal and David Wishart and Maria Mancini and David Sidransky and Bryan Kolb and Olga Kovalchuk",
year = "2018",
month = "2",
day = "20",
doi = "10.3389/fgene.2018.00041",
language = "English (US)",
volume = "9",
journal = "Frontiers in Genetics",
issn = "1664-8021",
publisher = "Frontiers Media S. A.",
number = "FEB",

}

TY - JOUR

T1 - Growth of malignant non-CNS tumors alters brain metabolome

AU - Kovalchuk, Anna

AU - Nersisyan, Lilit

AU - Mandal, Rupasri

AU - Wishart, David

AU - Mancini, Maria

AU - Sidransky, David

AU - Kolb, Bryan

AU - Kovalchuk, Olga

PY - 2018/2/20

Y1 - 2018/2/20

N2 - Cancer survivors experience numerous treatment side effects that negatively affect their quality of life. Cognitive side effects are especially insidious, as they affect memory, cognition, and learning. Neurocognitive deficits occur prior to cancer treatment, arising even before cancer diagnosis, and we refer to them as "tumor brain." Metabolomics is a new area of research that focuses on metabolome profiles and provides important mechanistic insights into various human diseases, including cancer, neurodegenerative diseases, and aging. Many neurological diseases and conditions affect metabolic processes in the brain. However, the tumor brain metabolome has never been analyzed. In our study we used direct flow injection/mass spectrometry (DI-MS) analysis to establish the effects of the growth of lung cancer, pancreatic cancer, and sarcoma on the brain metabolome of TumorGraft™ mice. We found that the growth of malignant non-CNS tumors impacted metabolic processes in the brain, affecting protein biosynthesis, and amino acid and sphingolipid metabolism. The observed metabolic changes were similar to those reported for neurodegenerative diseases and brain aging, and may have potential mechanistic value for future analysis of the tumor brain phenomenon.

AB - Cancer survivors experience numerous treatment side effects that negatively affect their quality of life. Cognitive side effects are especially insidious, as they affect memory, cognition, and learning. Neurocognitive deficits occur prior to cancer treatment, arising even before cancer diagnosis, and we refer to them as "tumor brain." Metabolomics is a new area of research that focuses on metabolome profiles and provides important mechanistic insights into various human diseases, including cancer, neurodegenerative diseases, and aging. Many neurological diseases and conditions affect metabolic processes in the brain. However, the tumor brain metabolome has never been analyzed. In our study we used direct flow injection/mass spectrometry (DI-MS) analysis to establish the effects of the growth of lung cancer, pancreatic cancer, and sarcoma on the brain metabolome of TumorGraft™ mice. We found that the growth of malignant non-CNS tumors impacted metabolic processes in the brain, affecting protein biosynthesis, and amino acid and sphingolipid metabolism. The observed metabolic changes were similar to those reported for neurodegenerative diseases and brain aging, and may have potential mechanistic value for future analysis of the tumor brain phenomenon.

KW - Animal models

KW - Brain aging

KW - Metabolomics/metabolite profiling

KW - Non-CNS tumors

KW - Tumor brain

UR - http://www.scopus.com/inward/record.url?scp=85042510395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042510395&partnerID=8YFLogxK

U2 - 10.3389/fgene.2018.00041

DO - 10.3389/fgene.2018.00041

M3 - Article

C2 - 29515623

AN - SCOPUS:85042510395

VL - 9

JO - Frontiers in Genetics

JF - Frontiers in Genetics

SN - 1664-8021

IS - FEB

M1 - 41

ER -